Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis

Background: The use of ipilimumab, nivolumab, and pembrolizumab as monotherapies or in combination has transformed the management of advanced melanoma even though these drugs are associated with a new profile of immune-related adverse events (irAEs). The incidence of irAEs from clinical trials of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Almutairi, Abdulaali R., McBride, Ali, Slack, Marion, Erstad, Brian L., Abraham, Ivo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033582/
https://www.ncbi.nlm.nih.gov/pubmed/32117745
http://dx.doi.org/10.3389/fonc.2020.00091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033582/
https://www.ncbi.nlm.nih.gov/pubmed/32117745
http://dx.doi.org/10.3389/fonc.2020.00091

Ejemplares similares